Literature DB >> 31192473

Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy.

Floor C Loonstra1, Inge M W Verberk2, Martijn T Wijburg1,3, Mike P Wattjes3,4, Charlotte E Teunissen2, Bob W van Oosten1, Bernard M J Uitdehaag1, Joep Killestein1, Zoé L E van Kempen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31192473     DOI： 10.1002/ana.25523

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  2 in total

1.  Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis.

Authors:  Undine Proschmann; Hernan Inojosa; Katja Akgün; Tjalf Ziemssen
Journal:  Front Neurol       Date:  2021-04-14       Impact factor: 4.003

2.  Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab.

Authors:  Alyssa A Toorop; Zoë Y G van Lierop; Eva E M Strijbis; Charlotte E Teunissen; Axel Petzold; Mike P Wattjes; Frederik Barkhof; Brigit A de Jong; Zoé L E van Kempen; Joep Killestein
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-10-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.